EMEA-003497-PIP01-23 - paediatric investigation plan
Oregovomab
PIPHuman
Key facts
- Active Substance
- Oregovomab
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0514/2023
- PIP number
- EMEA-003497-PIP01-23
- Pharmaceutical form(s)
- Powder for solution for infusion
- Condition(s) / indication(s)
- Treatment of fallopian tube cancer
- Treatment of ovarian cancer
- Treatment of primary peritoneal cancer
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Canariabio Inc.
E-mail: ben.yoon@canariabio.com
Tel: +82 1042678593- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date